<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36358996</PMID><DateCompleted><Year>2022</Year><Month>11</Month><Day>14</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2218-273X</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>11</Issue><PubDate><Year>2022</Year><Month>Nov</Month><Day>07</Day></PubDate></JournalIssue><Title>Biomolecules</Title><ISOAbbreviation>Biomolecules</ISOAbbreviation></Journal><ArticleTitle>Possible Application of Melatonin in Long COVID.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1646</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/biom12111646</ELocationID><Abstract><AbstractText>Clinical sequelae and symptoms for a considerable number of COVID-19 patients can linger for months beyond the acute stage of SARS-CoV-2 infection, "long COVID". Among the long-term consequences of SARS-CoV-2 infection, cognitive issues (especially memory loss or "brain fog"), chronic fatigue, myalgia, and muscular weakness resembling myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) are of importance. Melatonin may be particularly effective at reducing the signs and symptoms of SARS-CoV-2 infection due to its functions as an antioxidant, anti-inflammatory, and immuno-modulatory agent. Melatonin is also a chronobiotic medication effective in treating delirium and restoring the circadian imbalance seen in COVID patients in the intensive care unit. Additionally, as a cytoprotector, melatonin aids in the prevention of several COVID-19 comorbidities, including diabetes, metabolic syndrome, and ischemic and non-ischemic cardiovascular diseases. This narrative review discusses the application of melatonin as a neuroprotective agent to control cognitive deterioration ("brain fog") and pain in the ME/CFS syndrome-like documented in long COVID. Further studies on the therapeutic use of melatonin in the neurological sequelae of SARS-CoV-2 infection are warranted.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cardinali</LastName><ForeName>Daniel P</ForeName><Initials>DP</Initials><AffiliationInfo><Affiliation>Faculty of Medical Sciences, Pontificia Universidad Cat&#xf3;lica Argentina, Buenos Aires C1107AAZ, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brown</LastName><ForeName>Gregory M</ForeName><Initials>GM</Initials><AffiliationInfo><Affiliation>Centre for Addiction and Mental Health, Department of Psychiatry, University of Toronto, Toronto, ON M5T 1R8, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pandi-Perumal</LastName><ForeName>Seithikurippu R</ForeName><Initials>SR</Initials><Identifier Source="ORCID">0000-0002-8686-7259</Identifier><AffiliationInfo><Affiliation>Saveetha Medical College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai 600077, India.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>11</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Biomolecules</MedlineTA><NlmUniqueID>101596414</NlmUniqueID><ISSNLinking>2218-273X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>JL5DK93RCL</RegistryNumber><NameOfSubstance UI="D008550">Melatonin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008550" MajorTopicYN="Y">Melatonin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015673" MajorTopicYN="Y">Fatigue Syndrome, Chronic</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="Y">COVID-19 Drug Treatment</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2 virus</Keyword><Keyword MajorTopicYN="N">brain fog</Keyword><Keyword MajorTopicYN="N">fibromyalgia</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">melatonin</Keyword><Keyword MajorTopicYN="N">minimal cognitive impairment</Keyword><Keyword MajorTopicYN="N">myalgic encephalomyelitis/chronic fatigue syndrome</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>10</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>11</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>11</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>11</Day><Hour>1</Hour><Minute>8</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>11</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36358996</ArticleId><ArticleId IdType="pmc">PMC9687267</ArticleId><ArticleId IdType="doi">10.3390/biom12111646</ArticleId><ArticleId IdType="pii">biom12111646</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Center for Systems Science and Engineering (CSSE) 2022 COVID-19 Map&#x2014;Johns Hopkins Coronavirus Resource Center.  [(accessed on 9 October 2022)].  Available online:  https://coronavirus.jhu.edu/map.html.</Citation></Reference><Reference><Citation>Ahmad S.J., Feigen C.M., Vazquez J.P., Kobets A.J., Altschul D.J., Franco R., Emerald M. Neurological Sequelae of COVID-19. J. Integr. Neurosci. 2022;21:77. doi: 10.31083/j.jin2103077.</Citation><ArticleIdList><ArticleId IdType="doi">10.31083/j.jin2103077</ArticleId><ArticleId IdType="pubmed">35633158</ArticleId></ArticleIdList></Reference><Reference><Citation>Hope A.A., Evering T.H. Postacute Sequelae of Severe Acute Respiratory Syndrome Coronavirus 2 Infection. Infect. Dis. Clin. N. Am. 2022;36:379&#x2013;395. doi: 10.1016/j.idc.2022.02.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.idc.2022.02.004</ArticleId><ArticleId IdType="pmc">PMC8843334</ArticleId><ArticleId IdType="pubmed">35636906</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Aly Z., Bowe B., Xie Y. Long COVID after Breakthrough SARS-CoV-2 Infection. Nat. Med. 2022;28:1461&#x2013;1467. doi: 10.1038/s41591-022-01840-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01840-0</ArticleId><ArticleId IdType="pmc">PMC9307472</ArticleId><ArticleId IdType="pubmed">35614233</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang M., Liang Y., Yu D., Du B., Cheng W., Li L., Yu Z., Luo S., Zhang Y., Wang H., et al. A Systematic Review of Vaccine Breakthrough Infections by SARS-CoV-2 Delta Variant. Int. J. Biol. Sci. 2022;18:889&#x2013;900. doi: 10.7150/ijbs.68973.</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/ijbs.68973</ArticleId><ArticleId IdType="pmc">PMC8741840</ArticleId><ArticleId IdType="pubmed">35002532</ArticleId></ArticleIdList></Reference><Reference><Citation>Christopher Perry J., Bekes V., Starrs C.J. A Systematic Survey of Adults&#x2019; Health-Protective Behavior Use during Early COVID-19 Pandemic in Canada, Germany, United Kingdom, and the United States, and Vaccination Hesitancy and Status Eight Months Later. Prev. Med. Rep. 2022:102013. doi: 10.1016/j.pmedr.2022.102013. ahead of print .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pmedr.2022.102013</ArticleId><ArticleId IdType="pmc">PMC9554196</ArticleId><ArticleId IdType="pubmed">36246769</ArticleId></ArticleIdList></Reference><Reference><Citation>Juthani P.V., Gupta A., Borges K.A., Price C.C., Lee A.I., Won C.H., Chun H.J. Hospitalisation among Vaccine Breakthrough COVID-19 Infections. Lancet Infect. Dis. 2021;21:1485&#x2013;1486. doi: 10.1016/S1473-3099(21)00558-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00558-2</ArticleId><ArticleId IdType="pmc">PMC8423430</ArticleId><ArticleId IdType="pubmed">34506735</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet M., Sillett R., Zhu L., Mendel J., Camplisson I., Dercon Q., Harrison P.J. Neurological and Psychiatric Risk Trajectories after SARS-CoV-2 Infection: An Analysis of 2-Year Retrospective Cohort Studies Including 1,284,437 Patients. Lancet Psychiatry. 2022;9:815&#x2013;827. doi: 10.1016/S2215-0366(22)00260-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2215-0366(22)00260-7</ArticleId><ArticleId IdType="pmc">PMC9385200</ArticleId><ArticleId IdType="pubmed">35987197</ArticleId></ArticleIdList></Reference><Reference><Citation>Acu&#xf1;a-Castroviejo D., Escames G., Figueira J.C., de la Oliva P., Borobia A.M., Acu&#xf1;a-Fern&#xe1;ndez C. Clinical Trial to Test the Efficacy of Melatonin in COVID-19. J. Pineal Res. 2020;69:e12683. doi: 10.1111/jpi.12683.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jpi.12683</ArticleId><ArticleId IdType="pmc">PMC7435535</ArticleId><ArticleId IdType="pubmed">32770854</ArticleId></ArticleIdList></Reference><Reference><Citation>Artigas L., Coma M., Matos-Filipe P., Aguirre-Plans J., Farr&#xe9;s J., Valls R., Fernandez-Fuentes N., De La Haba-Rodriguez J., Olvera A., Barbera J., et al. In-Silico Drug Repurposing Study Predicts the Combination of Pirfenidone and Melatonin as a Promising Candidate Therapy to Reduce SARS-CoV-2 Infection Progression and Respiratory Distress Caused by Cytokine Storm. PLoS ONE. 2020;15:e0240149. doi: 10.1371/journal.pone.0240149.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0240149</ArticleId><ArticleId IdType="pmc">PMC7531795</ArticleId><ArticleId IdType="pubmed">33006999</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardinali D.P. High Doses of Melatonin as a Potential Therapeutic Tool for the Neurologic Sequels of COVID-19 Infection. Melatonin Res. 2020;3:311&#x2013;317. doi: 10.32794/mr11250064.</Citation><ArticleIdList><ArticleId IdType="doi">10.32794/mr11250064</ArticleId></ArticleIdList></Reference><Reference><Citation>Simko F., Hrenak J., Dominguez-Rodriguez A., Reiter R.J. Melatonin as a Putative Protection against Myocardial Injury in COVID-19 Infection. Expert Rev. Clin. Pharmacol. 2020;13:921&#x2013;924. doi: 10.1080/17512433.2020.1814141.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17512433.2020.1814141</ArticleId><ArticleId IdType="pubmed">32893686</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiter R.J., Sharma R., Ma Q., Dominquez-Rodriguez A., Marik P.E., Abreu-Gonzalez P. Melatonin Inhibits COVID-19-Induced Cytokine Storm by Reversing Aerobic Glycolysis in Immune Cells: A Mechanistic Analysis. Med. Drug Discov. 2020;6:100044. doi: 10.1016/j.medidd.2020.100044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.medidd.2020.100044</ArticleId><ArticleId IdType="pmc">PMC7211589</ArticleId><ArticleId IdType="pubmed">32395713</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardinali D.P., Brown G.M., Pandi-Perumal S.R. Can Melatonin Be a Potential &#x201c;Silver Bullet&#x201d; in Treating COVID-19 Patients? Diseases. 2020;8:44. doi: 10.3390/diseases8040044.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/diseases8040044</ArticleId><ArticleId IdType="pmc">PMC7709121</ArticleId><ArticleId IdType="pubmed">33256258</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarrott B., Head R., Pringle K.G., Lumbers E.R., Martin J.H. &#x201c;LONG COVID&#x201d;&#x2014;A Hypothesis for Understanding the Biological Basis and Pharmacological Treatment Strategy. Pharmacol. Res. Perspect. 2022;10:e00911. doi: 10.1002/prp2.911.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/prp2.911</ArticleId><ArticleId IdType="pmc">PMC8929332</ArticleId><ArticleId IdType="pubmed">35029046</ArticleId></ArticleIdList></Reference><Reference><Citation>Markousis Mavrogenis G., Bacopoulou F., Kolovou G., Pons M.-R., Giannakopoulou A., Papavasiliou A., Kitas G., Chrousos G., Mavrogeni S. Pathophysiology of Cognitive Dysfunction and the Role of Combined Brain/Heart Magnetic Resonance Imaging (Review) Exp. Ther. Med. 2022;24:569. doi: 10.3892/etm.2022.11506.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/etm.2022.11506</ArticleId><ArticleId IdType="pmc">PMC9366250</ArticleId><ArticleId IdType="pubmed">35978932</ArticleId></ArticleIdList></Reference><Reference><Citation>Campos M.C., Nery T., Starke A.C., Cristina A., Alves B., Speck A.E., Aguiar A.S. Post-Viral Fatigue in COVID-19: A Review of Symptom Assessment Methods, Mental, Cognitive, and Physical Impairment. Neurosci. Biobehav. Rev. 2022;142:104902. doi: 10.1016/j.neubiorev.2022.104902.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neubiorev.2022.104902</ArticleId><ArticleId IdType="pmc">PMC9528075</ArticleId><ArticleId IdType="pubmed">36202253</ArticleId></ArticleIdList></Reference><Reference><Citation>Nuzzo D., Vasto S., Scalisi L., Cottone S., Cambula G., Rizzo M., Giacomazza D., Picone P. Post-Acute COVID-19 Neurological Syndrome: A New Medical Challenge. J. Clin. Med. 2021;10:1947. doi: 10.3390/jcm10091947.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm10091947</ArticleId><ArticleId IdType="pmc">PMC8124354</ArticleId><ArticleId IdType="pubmed">34062770</ArticleId></ArticleIdList></Reference><Reference><Citation>Diem L., Fregolente-Gomes L., Warncke J.D., Hammer H., Friedli C., Kamber N., Jung S., Bigi S., Funke-Chambour M., Chan A., et al. Fatigue in Post-COVID-19 Syndrome: Clinical Phenomenology, Comorbidities and Association with Initial Course of COVID-19. J. Cent. Nerv. Syst. Dis. 2022;14:117957352211027. doi: 10.1177/11795735221102727.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/11795735221102727</ArticleId><ArticleId IdType="pmc">PMC9130865</ArticleId><ArticleId IdType="pubmed">35633835</ArticleId></ArticleIdList></Reference><Reference><Citation>Hugon J., Msika E.F., Queneau M., Farid K., Paquet C. Long COVID: Cognitive Complaints (Brain Fog) and Dysfunction of the Cingulate Cortex. J. Neurol. 2022;269:44&#x2013;46. doi: 10.1007/s00415-021-10655-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-021-10655-x</ArticleId><ArticleId IdType="pmc">PMC8211714</ArticleId><ArticleId IdType="pubmed">34143277</ArticleId></ArticleIdList></Reference><Reference><Citation>Hampshire A., Trender W., Chamberlain S.R., Jolly A.E., Grant J.E., Patrick F., Mazibuko N., Williams S.C., Barnby J.M., Hellyer P., et al. Cognitive Deficits in People Who Have Recovered from COVID-19. EClinicalMedicine. 2021;39:101044. doi: 10.1016/j.eclinm.2021.101044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2021.101044</ArticleId><ArticleId IdType="pmc">PMC8298139</ArticleId><ArticleId IdType="pubmed">34316551</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdelnour C., Agosta F., Bozzali M., Foug&#xe8;re B., Iwata A., Nilforooshan R., Takada L.T., Vi&#xf1;uela F., Traber M. Perspectives and Challenges in Patient Stratification in Alzheimer&#x2019;s Disease. Alzheimers Res. Ther. 2022;14:112. doi: 10.1186/s13195-022-01055-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-022-01055-y</ArticleId><ArticleId IdType="pmc">PMC9375274</ArticleId><ArticleId IdType="pubmed">35964143</ArticleId></ArticleIdList></Reference><Reference><Citation>Renz-Polster H., Scheibenbogen C. Post-COVID Syndrome with Fatigue and Exercise Intolerance: Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Inn. Med. 2022;63:830&#x2013;839. doi: 10.1007/s00108-022-01369-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00108-022-01369-x</ArticleId><ArticleId IdType="pmc">PMC9281337</ArticleId><ArticleId IdType="pubmed">35925074</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris G., Puri B.K., Walker A.J., Maes M., Carvalho A.F., Walder K., Mazza C., Berk M. Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: From Pathophysiological Insights to Novel Therapeutic Opportunities. Pharmacol. Res. 2019;148:104450. doi: 10.1016/j.phrs.2019.104450.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phrs.2019.104450</ArticleId><ArticleId IdType="pubmed">31509764</ArticleId></ArticleIdList></Reference><Reference><Citation>McCarthy M.J. Circadian Rhythm Disruption in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Implications for the Post-Acute Sequelae of COVID-19. Brain Behav. Immun. Health. 2022;20:100412. doi: 10.1016/j.bbih.2022.100412.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbih.2022.100412</ArticleId><ArticleId IdType="pmc">PMC9019698</ArticleId><ArticleId IdType="pubmed">35465246</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Y., Shang Y., Song W., Li Q., Xie H., Xu Q., Jia J., Li L., Mao H., Zhou X., et al. Follow-up Study of the Pulmonary Function and Related Physiological Characteristics of COVID-19 Survivors Three Months after Recovery. EClinicalMedicine. 2020;25:100463. doi: 10.1016/j.eclinm.2020.100463.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2020.100463</ArticleId><ArticleId IdType="pmc">PMC7361108</ArticleId><ArticleId IdType="pubmed">32838236</ArticleId></ArticleIdList></Reference><Reference><Citation>Kedor C., Freitag H., Meyer-Arndt L., Wittke K., Hanitsch L.G., Zoller T., Steinbeis F., Haffke M., Rudolf G., Heidecker B., et al. A Prospective Observational Study of Post-COVID-19 Chronic Fatigue Syndrome Following the First Pandemic Wave in Germany and Biomarkers Associated with Symptom Severity. Nat. Commun. 2022;13:5104. doi: 10.1038/s41467-022-32507-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-32507-6</ArticleId><ArticleId IdType="pmc">PMC9426365</ArticleId><ArticleId IdType="pubmed">36042189</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis H.E., Assaf G.S., McCorkell L., Wei H., Low R.J., Re&#x2019;em Y., Redfield S., Austin J.P., Akrami A. Characterizing Long COVID in an International Cohort: 7 Months of Symptoms and Their Impact. EClinicalMedicine. 2021;38:101019. doi: 10.1016/j.eclinm.2021.101019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2021.101019</ArticleId><ArticleId IdType="pmc">PMC8280690</ArticleId><ArticleId IdType="pubmed">34308300</ArticleId></ArticleIdList></Reference><Reference><Citation>Maestroni G.J.M. Therapeutic Potential of Melatonin in Immunodeficiency States, Viral Diseases, and Cancer. In Proceedings of the Advances in Experimental Medicine and Biology. Adv. Exp. Med. Biol. 2000;467:217&#x2013;226.</Citation><ArticleIdList><ArticleId IdType="pubmed">10721059</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson G., Maes M., Markus R.P., Rodriguez M. Ebola Virus: Melatonin as a Readily Available Treatment Option. J. Med. Virol. 2015;87:537&#x2013;543. doi: 10.1002/jmv.24130.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.24130</ArticleId><ArticleId IdType="pubmed">25611054</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardinali D.P. Melatonin: Clinical Perspectives in Neurodegeneration. Front. Endocrinol. 2019;10:480. doi: 10.3389/fendo.2019.00480.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fendo.2019.00480</ArticleId><ArticleId IdType="pmc">PMC6646522</ArticleId><ArticleId IdType="pubmed">31379746</ArticleId></ArticleIdList></Reference><Reference><Citation>Reynolds J.L., Dubocovich M.L. Melatonin Multifaceted Pharmacological Actions on Melatonin Receptors Converging to Abrogate COVID-19. J. Pineal Res. 2021;71:e12732. doi: 10.1111/jpi.12732.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jpi.12732</ArticleId><ArticleId IdType="pmc">PMC8250125</ArticleId><ArticleId IdType="pubmed">33759236</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardeland R. Melatonin and Inflammation&#x2014;Story of a Double-Edged Blade. J. Pineal Res. 2018;65:e12525. doi: 10.1111/jpi.12525.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jpi.12525</ArticleId><ArticleId IdType="pubmed">30242884</ArticleId></ArticleIdList></Reference><Reference><Citation>da Cunha Pedrosa A.M., Weinlich R., Mognol G.P., Robbs B.K., de Biaso Viola J.P., Campa A., Amarante-Mendes G.P. Melatonin Protects CD4+ T Cells from Activation-Induced Cell Death by Blocking NFAT-Mediated CD95 Ligand Upregulation. J. Immunol. 2010;184:3487&#x2013;3494. doi: 10.4049/jimmunol.0902961.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.0902961</ArticleId><ArticleId IdType="pubmed">20181888</ArticleId></ArticleIdList></Reference><Reference><Citation>Shang Y., Xu S.P., Wu Y., Jiang Y.X., Wu Z.Y., Yuan S.Y., Yao S.L. Melatonin Reduces Acute Lung Injury in Endotoxemic Rats. Chin. Med. J. 2009;122:1388&#x2013;1393. doi: 10.3760/cma.j.issn.0366-6999.2009.12.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.3760/cma.j.issn.0366-6999.2009.12.006</ArticleId><ArticleId IdType="pubmed">19567158</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmadi Z., Ashrafizadeh M. Melatonin as a Potential Modulator of Nrf2. Fundam. Clin. Pharmacol. 2020;34:11&#x2013;19. doi: 10.1111/fcp.12498.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/fcp.12498</ArticleId><ArticleId IdType="pubmed">31283051</ArticleId></ArticleIdList></Reference><Reference><Citation>Habtemariam S., Daglia M., Sureda A., Selamoglu Z., Fuat Gulhan M., Mohammad Nabavi S. Melatonin and Respiratory Diseases: A Review. Curr. Top. Med. Chem. 2017;17:467&#x2013;488. doi: 10.2174/1568026616666160824120338.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1568026616666160824120338</ArticleId><ArticleId IdType="pubmed">27558675</ArticleId></ArticleIdList></Reference><Reference><Citation>Manchester L.C., Coto-Montes A., Boga J.A., Andersen L.P.H., Zhou Z., Galano A., Vriend J., Tan D.X., Reiter R.J. Melatonin: An Ancient Molecule That Makes Oxygen Metabolically Tolerable. J. Pineal Res. 2015;59:403&#x2013;419. doi: 10.1111/jpi.12267.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jpi.12267</ArticleId><ArticleId IdType="pubmed">26272235</ArticleId></ArticleIdList></Reference><Reference><Citation>Galano A., Tan D.X., Reiter R.J. Melatonin as a Natural Ally against Oxidative Stress: A Physicochemical Examination. J. Pineal Res. 2011;51:1&#x2013;16. doi: 10.1111/j.1600-079X.2011.00916.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-079X.2011.00916.x</ArticleId><ArticleId IdType="pubmed">21752095</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiter R.J., Tan D.X., Rosales-Corral S., Galano A., Jou M.J., Acuna-Castroviejo D. Melatonin Mitigates Mitochondrial Meltdown: Interactions with SIRT3. Int. J. Mol. Sci. 2018;19:2439. doi: 10.3390/ijms19082439.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms19082439</ArticleId><ArticleId IdType="pmc">PMC6121285</ArticleId><ArticleId IdType="pubmed">30126181</ArticleId></ArticleIdList></Reference><Reference><Citation>Bar-Or D., Carrick M., Tanner A., Lieser M.J., Rael L.T., Brody E. Overcoming the Warburg Effect: Is It the Key to Survival in Sepsis? J. Crit. Care. 2018;43:197&#x2013;201. doi: 10.1016/j.jcrc.2017.09.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcrc.2017.09.012</ArticleId><ArticleId IdType="pubmed">28915394</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian M., Liu W., Li X., Zhao P., Shereen M.A., Zhu C., Huang S., Liu S., Yu X., Yue M., et al. HIF-1&#x3b1; Promotes SARS-CoV-2 Infection and Aggravates Inflammatory Responses to COVID-19. Signal Transduct. Target. Ther. 2021;6:308. doi: 10.1038/s41392-021-00726-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-021-00726-w</ArticleId><ArticleId IdType="pmc">PMC8371950</ArticleId><ArticleId IdType="pubmed">34408131</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiter R.J., Sharma R., Rosales-Corral S. Anti-Warburg Effect of Melatonin: A Proposed Mechanism to Explain Its Inhibition of Multiple Diseases. Int. J. Mol. Sci. 2021;22:764. doi: 10.3390/ijms22020764.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22020764</ArticleId><ArticleId IdType="pmc">PMC7828708</ArticleId><ArticleId IdType="pubmed">33466614</ArticleId></ArticleIdList></Reference><Reference><Citation>Owczarek A., Gieczewska K.B., Polanska M., Paterczyk B., Gruza A., Winiarska K. Melatonin Lowers HIF-1&#x3b1; Content in Human Proximal Tubular Cells (HK-2) Due to Preventing Its Deacetylation by Sirtuin 1. Front. Physiol. 2020;11:572911. doi: 10.3389/fphys.2020.572911.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphys.2020.572911</ArticleId><ArticleId IdType="pmc">PMC7841413</ArticleId><ArticleId IdType="pubmed">33519498</ArticleId></ArticleIdList></Reference><Reference><Citation>Moniruzzaman M., Ghosal I., Das D., Chakraborty S.B. Melatonin Ameliorates H2O2-Induced Oxidative Stress through Modulation of Erk/Akt/NFkB Pathway. Biol. Res. 2018;51:17. doi: 10.1186/s40659-018-0168-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40659-018-0168-5</ArticleId><ArticleId IdType="pmc">PMC5996524</ArticleId><ArticleId IdType="pubmed">29891016</ArticleId></ArticleIdList></Reference><Reference><Citation>Saha M., Manna K., das Saha K. Melatonin Suppresses NLRP3 Inflammasome Activation via TLR4/NF-&#x39a;B and P2X7R Signaling in High-Fat Diet-Induced Murine NASH Model. J. Inflamm. Res. 2022;15:3235&#x2013;3258. doi: 10.2147/JIR.S343236.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/JIR.S343236</ArticleId><ArticleId IdType="pmc">PMC9166960</ArticleId><ArticleId IdType="pubmed">35668917</ArticleId></ArticleIdList></Reference><Reference><Citation>Snider J.M., You J.K., Wang X., Snider A.J., Hallmark B., Zec M.M., Seeds M.C., Sergeant S., Johnstone L., Wang Q., et al. Group IIA Secreted Phospholipase A2 Is Associated with the Pathobiology Leading to COVID-19 Mortality. J. Clin. Investig. 2021;131:e149236. doi: 10.1172/JCI149236.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI149236</ArticleId><ArticleId IdType="pmc">PMC8483752</ArticleId><ArticleId IdType="pubmed">34428181</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng W.G., Tang S.T., Tseng H.P., Wu K.K. Melatonin Suppresses Macrophage Cyclooxygenase-2 and Inducible Nitric Oxide Synthase Expression by Inhibiting P52 Acetylation and Binding. Blood. 2006;108:518&#x2013;524. doi: 10.1182/blood-2005-09-3691.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2005-09-3691</ArticleId><ArticleId IdType="pmc">PMC1895491</ArticleId><ArticleId IdType="pubmed">16609073</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardinali D.P., Ritta M.N., Fuentes A.M., Gimeno M.F., Gimeno A.L. Prostaglandin E Release by Rat Medial Basal Hypothalamus in Vitro. Inhibition by Melatonin at Submicromolar Concentrations. Eur. J. Pharmacol. 1980;67:151&#x2013;153. doi: 10.1016/0014-2999(80)90025-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0014-2999(80)90025-4</ArticleId><ArticleId IdType="pubmed">7418729</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferracioli-Oda E., Qawasmi A., Bloch M.H. Meta-Analysis: Melatonin for the Treatment of Primary Sleep Disorders. PLoS ONE. 2013;8:e63773. doi: 10.1371/journal.pone.0063773.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0063773</ArticleId><ArticleId IdType="pmc">PMC3656905</ArticleId><ArticleId IdType="pubmed">23691095</ArticleId></ArticleIdList></Reference><Reference><Citation>Auld F., Maschauer E.L., Morrison I., Skene D.J., Riha R.L. Evidence for the Efficacy of Melatonin in the Treatment of Primary Adult Sleep Disorders. Sleep Med. Rev. 2017;34:10&#x2013;22. doi: 10.1016/j.smrv.2016.06.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.smrv.2016.06.005</ArticleId><ArticleId IdType="pubmed">28648359</ArticleId></ArticleIdList></Reference><Reference><Citation>Li T., Jiang S., Han M., Yang Z., Lv J., Deng C., Reiter R.J., Yang Y. Exogenous Melatonin as a Treatment for Secondary Sleep Disorders: A Systematic Review and Meta-Analysis. Front. Neuroendocrinol. 2019;52:22&#x2013;28. doi: 10.1016/j.yfrne.2018.06.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yfrne.2018.06.004</ArticleId><ArticleId IdType="pubmed">29908879</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson S.J., Nutt D.J., Alford C., Argyropoulos S.V., Baldwin D.S., Bateson A.N., Britton T.C., Crowe C., Dijk D.J., Espie C.A., et al. British Association for Psychopharmacology Consensus Statement on Evidence-Based Treatment of Insomnia, Parasomnias and Circadian Rhythm Disorders. J. Psychopharmacol. 2010;24:1577&#x2013;1600. doi: 10.1177/0269881110379307.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0269881110379307</ArticleId><ArticleId IdType="pubmed">20813762</ArticleId></ArticleIdList></Reference><Reference><Citation>Geoffroy P.A., Micoulaud Franchi J.A., Lopez R., Schroder C.M. The Use of Melatonin in Adult Psychiatric Disorders: Expert Recommendations by the French Institute of Medical Research on Sleep (SFRMS) Encephale. 2019;45:413&#x2013;423. doi: 10.1016/j.encep.2019.04.068.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.encep.2019.04.068</ArticleId><ArticleId IdType="pubmed">31248601</ArticleId></ArticleIdList></Reference><Reference><Citation>Palagini L., Manni R., Aguglia E., Amore M., Brugnoli R., Girardi P., Grassi L., Mencacci C., Plazzi G., Minervino A., et al. Expert Opinions and Consensus Recommendations for the Evaluation and Management of Insomnia in Clinical Practice: Joint Statements of Five Italian Scientific Societies. Front. Psychiatry. 2020;11:558. doi: 10.3389/fpsyt.2020.00558.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpsyt.2020.00558</ArticleId><ArticleId IdType="pmc">PMC7332855</ArticleId><ArticleId IdType="pubmed">32670104</ArticleId></ArticleIdList></Reference><Reference><Citation>Vecchierini M.F., Kilic-Huck U., Quera-Salva M.A. Melatonin (MEL) and Its Use in Neurological Diseases and Insomnia: Recommendations of the French Medical and Research Sleep Society (SFRMS) Rev. Neurol. 2020;177:245&#x2013;259. doi: 10.1016/j.neurol.2020.06.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurol.2020.06.009</ArticleId><ArticleId IdType="pubmed">32921425</ArticleId></ArticleIdList></Reference><Reference><Citation>Ibrahim M.G., Bellomo R., Hart G.K., Norman T., Goldsmith D., Bates S., Egi M. A Double-Blind Placebo-Controlled Randomised Pilot Study of Nocturnal Melatonin in Tracheostomised Patients. Crit. Care Resusc. 2006;8:187&#x2013;191.</Citation><ArticleIdList><ArticleId IdType="pubmed">16930101</ArticleId></ArticleIdList></Reference><Reference><Citation>Bourne R.S., Mills G.H., Minelli C. Melatonin Therapy to Improve Nocturnal Sleep in Critically Ill Patients: Encouraging Results from a Small Randomised Controlled Trial. Crit. Care. 2008;12:R52. doi: 10.1186/cc6871.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/cc6871</ArticleId><ArticleId IdType="pmc">PMC2447606</ArticleId><ArticleId IdType="pubmed">18423009</ArticleId></ArticleIdList></Reference><Reference><Citation>Foreman B., Westwood A.J., Claassen J., Bazil C.W. Sleep in the Neurological Intensive Care Unit: Feasibility of Quantifying Sleep after Melatonin Supplementation with Environmental Light and Noise Reduction. J. Clin. Neurophysiol. 2015;32:66&#x2013;74. doi: 10.1097/WNP.0000000000000110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WNP.0000000000000110</ArticleId><ArticleId IdType="pubmed">25647773</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellapart J., Boots R. Potential Use of Melatonin in Sleep and Delirium in the Critically Ill. Br. J. Anaesth. 2012;108:572&#x2013;580. doi: 10.1093/bja/aes035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bja/aes035</ArticleId><ArticleId IdType="pubmed">22419624</ArticleId></ArticleIdList></Reference><Reference><Citation>Soltani F., Salari A., Javaherforooshzadeh F., Nassajjian N., Kalantari F. The Effect of Melatonin on Reduction in the Need for Sedative Agents and Duration of Mechanical Ventilation in Traumatic Intracranial Hemorrhage Patients: A Randomized Controlled Trial. Eur. J. Trauma Emerg. Surg. 2020;48:545&#x2013;551. doi: 10.1007/s00068-020-01449-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00068-020-01449-3</ArticleId><ArticleId IdType="pmc">PMC7375205</ArticleId><ArticleId IdType="pubmed">32699918</ArticleId></ArticleIdList></Reference><Reference><Citation>Mistraletti G., Umbrello M., Miori S., Taverna M., Cerri B., Mantovani E., Formenti P., Spanu P., D&#x2019;Agostino A., Salini S., et al. Melatonin Reduces the Need for Sedation in ICU Patients: A Randomized Controlled Trial. Minerva Anestesiol. 2015;81:1298&#x2013;1310.</Citation><ArticleIdList><ArticleId IdType="pubmed">25969139</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardinali D.P., Brown G.M., Pandi-Perumal S.R. Melatonin&#x2019;s Benefits and Risks as a Therapy for Sleep Disturbances in the Elderly: Current Insights. Nat. Sci. Sleep. 2022;14:1843&#x2013;1855. doi: 10.2147/NSS.S380465.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/NSS.S380465</ArticleId><ArticleId IdType="pmc">PMC9578490</ArticleId><ArticleId IdType="pubmed">36267165</ArticleId></ArticleIdList></Reference><Reference><Citation>Valiensi S.M., Folgueira A., Vera V.A., Gonz&#xe1;lez Cardozo A., Cardinali D.P., Rugiero M. Pre-Pandemic Melatonin Treatment for Sleep Disorders and COVID-19 Infection. A Retrospective Cross-Sectional Study. Vertex. 2022;XXXIII:13&#x2013;24. doi: 10.53680/VERTEX.V33I155.132.</Citation><ArticleIdList><ArticleId IdType="doi">10.53680/VERTEX.V33I155.132</ArticleId><ArticleId IdType="pubmed">35438682</ArticleId></ArticleIdList></Reference><Reference><Citation>Cecon E., Izabelle C., Poder S.L., Real F., Zhu A., Tu L., Ghigna M.R., Klonjkowski B., Bomsel M., Jockers R., et al. Therapeutic Potential of Melatonin and Melatonergic Drugs on K18-HACE2 Mice Infected with SARS-CoV-2. J. Pineal Res. 2022;72:e12772. doi: 10.1111/jpi.12772.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jpi.12772</ArticleId><ArticleId IdType="pmc">PMC8646885</ArticleId><ArticleId IdType="pubmed">34586649</ArticleId></ArticleIdList></Reference><Reference><Citation>Reagan-Shaw S., Nihal M., Ahmad N. Dose Translation from Animal to Human Studies Revisited. FASEB J. 2008;22:659&#x2013;661. doi: 10.1096/fj.07-9574LSF.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.07-9574LSF</ArticleId><ArticleId IdType="pubmed">17942826</ArticleId></ArticleIdList></Reference><Reference><Citation>Abramov A.Y., Potapova E.V., Dremin V.V., Dunaev A.V. Interaction of Oxidative Stress and Misfolded Proteins in the Mechanism of Neurodegeneration. Life. 2020;10:101. doi: 10.3390/life10070101.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/life10070101</ArticleId><ArticleId IdType="pmc">PMC7400128</ArticleId><ArticleId IdType="pubmed">32629809</ArticleId></ArticleIdList></Reference><Reference><Citation>Corpas R., Gri&#xf1;&#xe1;n-Ferr&#xe9; C., Palomera-&#xc1;valos V., Porquet D., Garc&#xed;a de Frutos P., Franciscato Cozzolino S.M., Rodr&#xed;guez-Farr&#xe9; E., Pall&#xe0;s M., Sanfeliu C., Cardoso B.R. Melatonin Induces Mechanisms of Brain Resilience against Neurodegeneration. J. Pineal Res. 2018;65:e12515. doi: 10.1111/JPI.12515.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/JPI.12515</ArticleId><ArticleId IdType="pubmed">29907977</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeong S. Molecular and Cellular Basis of Neurodegeneration in Alzheimer&#x2019;s Disease. Mol. Cells. 2017;40:613&#x2013;620. doi: 10.14348/molcells.2017.0096.</Citation><ArticleIdList><ArticleId IdType="doi">10.14348/molcells.2017.0096</ArticleId><ArticleId IdType="pmc">PMC5638769</ArticleId><ArticleId IdType="pubmed">28927263</ArticleId></ArticleIdList></Reference><Reference><Citation>Shukla M., Chinchalongporn V., Govitrapong P., Reiter R.J. The Role of Melatonin in Targeting Cell Signaling Pathways in Neurodegeneration. Ann. N. Y. Acad. Sci. 2019;1443:75&#x2013;96. doi: 10.1111/nyas.14005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nyas.14005</ArticleId><ArticleId IdType="pubmed">30756405</ArticleId></ArticleIdList></Reference><Reference><Citation>Rehman S., Ikram M., Ullah N., Alam S., Park H., Badshah H., Choe K., Ok Kim M. Neurological Enhancement Effects of Melatonin against Brain Injury-Induced Oxidative Stress, Neuroinflammation, and Neurodegeneration via AMPK/CREB Signaling. Cells. 2019;8:760. doi: 10.3390/cells8070760.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells8070760</ArticleId><ArticleId IdType="pmc">PMC6678342</ArticleId><ArticleId IdType="pubmed">31330909</ArticleId></ArticleIdList></Reference><Reference><Citation>Pappolla M., Bozner P., Soto C., Shao H., Robakis N.K., Zagorski M., Frangione B., Ghiso J. Inhibition of Alzheimer Beta-Fibrillogenesis by Melatonin. J. Biol. Chem. 1998;273:7185&#x2013;7188. doi: 10.1074/jbc.273.13.7185.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.273.13.7185</ArticleId><ArticleId IdType="pubmed">9516407</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng Z., Zhang J.T. Protective Effect of Melatonin on Beta-Amyloid-Induced Apoptosis in Rat Astroglioma C6 Cells and Its Mechanism. Free Radic. Biol. Med. 2004;37:1790&#x2013;1801. doi: 10.1016/j.freeradbiomed.2004.08.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2004.08.023</ArticleId><ArticleId IdType="pubmed">15528038</ArticleId></ArticleIdList></Reference><Reference><Citation>Furio A.M., Cutrera R.A., Thea V.C., Lloret S.P., Riccio P., Caccuri R.L., Brusco L.I., Cardinali D.P. Effect of Melatonin on Changes in Locomotor Activity Rhythm of Syrian Hamsters Injected with Beta Amyloid Peptide 25&#x2013;35 in the Suprachiasmatic Nuclei. Cell. Mol. Neurobiol. 2002;22:699&#x2013;709. doi: 10.1023/A:1021805023906.</Citation><ArticleIdList><ArticleId IdType="doi">10.1023/A:1021805023906</ArticleId><ArticleId IdType="pubmed">12585689</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen Y.X., Xu S.Y., Wei W., Wang X.L., Wang H., Sun X. Melatonin Blocks Rat Hippocampal Neuronal Apoptosis Induced by Amyloid Beta-Peptide 25&#x2013;35. J. Pineal Res. 2002;32:163&#x2013;167. doi: 10.1034/j.1600-079x.2002.1o839.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1034/j.1600-079x.2002.1o839.x</ArticleId><ArticleId IdType="pubmed">12074099</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiong Y.F., Chen Q., Chen J., Zhou J., Wang H.X. Melatonin Reduces the Impairment of Axonal Transport and Axonopathy Induced by Calyculin A. J. Pineal Res. 2011;50:319&#x2013;327. doi: 10.1111/j.1600-079X.2010.00846.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-079X.2010.00846.x</ArticleId><ArticleId IdType="pubmed">21244478</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng Y.Q., Xu G.G., Duan P., Zhang Q., Wang J.Z. Effects of Melatonin on Wortmannin-Induced Tau Hyperphosphorylation. Acta Pharmacol. Sin. 2005;26:519&#x2013;526. doi: 10.1111/j.1745-7254.2005.00102.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1745-7254.2005.00102.x</ArticleId><ArticleId IdType="pubmed">15842767</ArticleId></ArticleIdList></Reference><Reference><Citation>Pappolla M.A., Matsubara E., Vidal R., Pacheco-Quinto J., Poeggeler B., Zagorski M., Sambamurti K. Melatonin Treatment Enhances A&#x3b2; Lymphatic Clearance in a Transgenic Mouse Model of Amyloidosis. Curr. Alzheimer Res. 2018;15:637&#x2013;642. doi: 10.2174/1567205015666180411092551.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1567205015666180411092551</ArticleId><ArticleId IdType="pmc">PMC8803126</ArticleId><ArticleId IdType="pubmed">29637859</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiter R.J., Sharma R., Rosales-Corral S., de Mange J., Phillips W.T., Tan D.X., Bitar R.D. Melatonin in Ventricular and Subarachnoid Cerebrospinal Fluid: Its Function in the Neural Glymphatic Network and Biological Significance for Neurocognitive Health. Biochem. Biophys. Res. Commun. 2022;605:70&#x2013;81. doi: 10.1016/j.bbrc.2022.03.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2022.03.025</ArticleId><ArticleId IdType="pubmed">35316766</ArticleId></ArticleIdList></Reference><Reference><Citation>Duffy J.F., Wang W., Ronda J.M., Czeisler C.A. High Dose Melatonin Increases Sleep Duration during Nighttime and Daytime Sleep Episodes in Older Adults. J. Pineal Res. 2022;73:e12801. doi: 10.1111/jpi.12801.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jpi.12801</ArticleId><ArticleId IdType="pmc">PMC9288519</ArticleId><ArticleId IdType="pubmed">35436355</ArticleId></ArticleIdList></Reference><Reference><Citation>Boespflug E.L., Iliff J.J. The Emerging Relationship Between Interstitial Fluid-Cerebrospinal Fluid Exchange, Amyloid-&#x3b2;, and Sleep. Biol. Psychiatry. 2018;83:328&#x2013;336. doi: 10.1016/j.biopsych.2017.11.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopsych.2017.11.031</ArticleId><ArticleId IdType="pmc">PMC5767516</ArticleId><ArticleId IdType="pubmed">29279202</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan S.H., Karri V., Tay N.W.R., Chang K.H., Ah H.Y., Ng P.Q., Ho H.S., Keh H.W., Candasamy M. Emerging Pathways to Neurodegeneration: Dissecting the Critical Molecular Mechanisms in Alzheimer&#x2019;s Disease, Parkinson&#x2019;s Disease. Biomed. Pharmacother. 2019;111:765&#x2013;777. doi: 10.1016/J.BIOPHA.2018.12.101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.BIOPHA.2018.12.101</ArticleId><ArticleId IdType="pubmed">30612001</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosales-Corral S., Tan D.X., Reiter R.J., Valdivia-Vel&#xe1;zquez M., Mart&#xed;nez-Barboza G., Acosta-Mart&#xed;nez J.P., Ortiz G.G. Orally Administered Melatonin Reduces Oxidative Stress and Proinflammatory Cytokines Induced by Amyloid-Beta Peptide in Rat Brain: A Comparative, in Vivo Study versus Vitamin C and E. J. Pineal Res. 2003;35:80&#x2013;84. doi: 10.1034/j.1600-079X.2003.00057.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1034/j.1600-079X.2003.00057.x</ArticleId><ArticleId IdType="pubmed">12887649</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W., Chen X., Su S., Jia Q., Ding T., Zhu Z., Zhang T. Exogenous Melatonin for Sleep Disorders in Neurodegenerative Diseases: A Meta-Analysis of Randomized Clinical Trials. Neurol. Sci. 2016;37:57&#x2013;65. doi: 10.1007/s10072-015-2357-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-015-2357-0</ArticleId><ArticleId IdType="pubmed">26255301</ArticleId></ArticleIdList></Reference><Reference><Citation>McCleery J., Sharpley A.L. Pharmacotherapies for Sleep Disturbances in Dementia. Cochrane Database Syst. Rev. 2020;11:CD009178. doi: 10.1002/14651858.CD009178.pub3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD009178.pub3</ArticleId><ArticleId IdType="pmc">PMC8094738</ArticleId><ArticleId IdType="pubmed">33189083</ArticleId></ArticleIdList></Reference><Reference><Citation>Furio A.M., Brusco L.I., Cardinali D.P. Possible Therapeutic Value of Melatonin in Mild Cognitive Impairment: A Retrospective Study. J. Pineal Res. 2007;43:404&#x2013;409. doi: 10.1111/j.1600-079X.2007.00491.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-079X.2007.00491.x</ArticleId><ArticleId IdType="pubmed">17910609</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardinali D.P., Vigo D.E., Olivar N., Vidal M.F., Furio A.M., Brusco L.I. Therapeutic Application of Melatonin in Mild Cognitive Impairment. Am. J. Neurodegener. Dis. 2012;1:280&#x2013;291.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3560473</ArticleId><ArticleId IdType="pubmed">23383398</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu L., Yu H., Sun H., Hu B., Geng Y. Dietary Melatonin Therapy Alleviates the Lamina Cribrosa Damages in Patients with Mild Cognitive Impairments: A Double-Blinded, Randomized Controlled Study. Med. Sci. Monit. 2020;26:e923232. doi: 10.12659/MSM.923232.</Citation><ArticleIdList><ArticleId IdType="doi">10.12659/MSM.923232</ArticleId><ArticleId IdType="pmc">PMC7233010</ArticleId><ArticleId IdType="pubmed">32376818</ArticleId></ArticleIdList></Reference><Reference><Citation>Sumsuzzman D.M., Choi J., Jin Y., Hong Y. Neurocognitive Effects of Melatonin Treatment in Healthy Adults and Individuals with Alzheimer&#x2019;s Disease and Insomnia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Neurosci. Biobehav. Rev. 2021;127:459&#x2013;473. doi: 10.1016/j.neubiorev.2021.04.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neubiorev.2021.04.034</ArticleId><ArticleId IdType="pubmed">33957167</ArticleId></ArticleIdList></Reference><Reference><Citation>Citera G., Arias M.A., Maldonado-Cocco J.A., L&#xe1;zaro M.A., Rosemffet M.G., Brusco L.I., Scheines E.J., Cardinalli D.P. The Effect of Melatonin in Patients with Fibromyalgia: A Pilot Study. Clin. Rheumatol. 2000;19:9&#x2013;13. doi: 10.1007/s100670050003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s100670050003</ArticleId><ArticleId IdType="pubmed">10752492</ArticleId></ArticleIdList></Reference><Reference><Citation>Hemati K., Amini Kadijani A., Sayehmiri F., Mehrzadi S., Zabihiyeganeh M., Hosseinzadeh A., Mirzaei A. Melatonin in the Treatment of Fibromyalgia Symptoms: A Systematic Review. Complement. Ther. Clin. Pract. 2020;38:101072. doi: 10.1016/j.ctcp.2019.101072.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ctcp.2019.101072</ArticleId><ArticleId IdType="pubmed">31783341</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson L.J., Gallagher P., Watson S., Pearce R., Finkelmeyer A., MacLachlan L., Newton J.L. Impairments in Cognitive Performance in Chronic Fatigue Syndrome Are Common, Not Related to Co-Morbid Depression but Do Associate with Autonomic Dysfunction. PLoS ONE. 2019;14:e0210394. doi: 10.1371/journal.pone.0210394.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0210394</ArticleId><ArticleId IdType="pmc">PMC6363139</ArticleId><ArticleId IdType="pubmed">30721241</ArticleId></ArticleIdList></Reference><Reference><Citation>PubMed 2022 Melatonin COVID&#x2014;Search Results&#x2014;PubMed.  [(accessed on 9 October 2022)]; Available online:  https://pubmed.ncbi.nlm.nih.gov/?term=melatonin+covid&amp;sort=pubdate&amp;size=50.</Citation></Reference><Reference><Citation>Castle R.D., Williams M.A., Bushell W.C., Rindfleisch J.A., Peterson C.T., Marzolf J., Brouwer K., Mills P.J. Implications for Systemic Approaches to COVID-19: Effect Sizes of Remdesivir, Tocilizumab, Melatonin, Vitamin D3, and Meditation. J. Inflamm. Res. 2021;14:4859&#x2013;4876. doi: 10.2147/JIR.S323356.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/JIR.S323356</ArticleId><ArticleId IdType="pmc">PMC8473718</ArticleId><ArticleId IdType="pubmed">34588793</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>